FibroBiologics Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>FibroBiologics Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to register securities for public sale.</b>

AI Summary

FibroBiologics Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on January 24, 2024. FibroBiologics, Inc. filed an amendment (S-1/A) to its registration statement on January 24, 2024. The company is incorporated in Delaware and its principal executive offices are located in Houston, Texas. The filing is for registration under the Securities Act of 1933, with registration number 333-275361. FibroBiologics Inc. is classified under Standard Industrial Classification code 2834 (Pharmaceutical Preparations). The company has elected not to use the extended transition period for complying with new or revised financial accounting standards.

Why It Matters

For investors and stakeholders tracking FibroBiologics Inc., this filing contains several important signals. This amendment suggests FibroBiologics is actively moving towards an initial public offering or further public sale of its securities. The filing provides updated information for potential investors regarding the company's structure, registration details, and compliance with accounting standards.

Risk Assessment

Risk Level: low — FibroBiologics Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for companies preparing to go public or conduct a securities offering, and does not contain new financial performance data or significant business updates that would inherently increase risk.

Analyst Insight

Monitor future filings for the effectiveness of the registration statement and details of the proposed securities offering.

Key Numbers

• 2024-01-24 — Filing Date (Date of S-1/A filing)
• 333-275361 — Registration Number (SEC registration number for the offering)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 86-3329066 — IRS Number (Employer Identification Number)

Key Players & Entities

• FibroBiologics Inc. (company) — Registrant name
• Pete O'Heeron (person) — Chief Executive Officer
• Norton Rose Fulbright US LLP (company) — Legal counsel
• Brian Fenske (person) — Contact at legal counsel
• 333-275361 (regulator) — SEC registration number
• 2834 (regulator) — Standard Industrial Classification Code

Forward-Looking Statements

• FibroBiologics Inc. will commence its proposed sale to the public shortly after this registration statement becomes effective. (FibroBiologics Inc.) — high confidence, target: Q1 2024

FAQ

Industry Context

FibroBiologics Inc. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of regenerative medicine products.

Regulatory Implications

The company is registering securities under the Securities Act of 1933, requiring adherence to SEC disclosure and registration rules.

What Investors Should Do

1. Review the full S-1/A filing for detailed disclosures on the company's business, financials, and risks.
2. Track the SEC's review process and any further amendments to the registration statement.
3. Monitor for the effectiveness of the registration statement and the subsequent offering of securities.

Key Dates

• 2024-01-24: S-1/A Filing — Amendment filed with the SEC

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous registration statement, indicating an update or correction rather than a new initial filing.

Key Financial Figures

• $6.76 — cement, at a price of the equivalent of $6.76 per share as to the equivalent of 318,0
• $18.00 — t prices ranging from the equivalent of $18.00 to the equivalent of $20.00 per share a
• $20.00 — uivalent of $18.00 to the equivalent of $20.00 per share as to the equivalent of 64,07

Filing Documents

• forms-1a.htm (S-1/A) — 2779KB
• ex23-2.htm (EX-23.2) — 5KB
• fdrs_001.jpg (GRAPHIC) — 4KB
• drs_1.jpg (GRAPHIC) — 18KB
• drs_2.jpg (GRAPHIC) — 18KB
• formdrs_005.jpg (GRAPHIC) — 6KB
• formdrs_006.jpg (GRAPHIC) — 7KB
• fdrs_004.jpg (GRAPHIC) — 18KB
• fdrs_005.jpg (GRAPHIC) — 15KB
• fdrs_006.jpg (GRAPHIC) — 11KB
• fdrs_007.jpg (GRAPHIC) — 12KB
• 0001493152-24-003511.txt (&nbsp;) — 2937KB

RISK FACTORS

RISK FACTORS 9 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 62 MARKET AND INDUSTRY DATA 63 TRADEMARKS, SERVICE MARKS AND TRADENAMES 64

USE OF PROCEEDS

USE OF PROCEEDS 65 DIVIDEND POLICY 65 CAPITALIZATION 65 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 66

BUSINESS

BUSINESS 77 MANAGEMENT 101 EXECUTIVE AND DIRECTOR COMPENSATION 108 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 113 PRINCIPAL AND REGISTERED STOCKHOLDERS 114

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 116 SHARES ELIGIBLE FOR FUTURE SALE 120 SALE PRICE HISTORY OF OUR CAPITAL STOCK 121 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 121 PLAN OF DISTRIBUTION 12 6 LEGAL MATTERS 129 EXPERTS 129 WHERE YOU CAN FIND ADDITIONAL INFORMATION 12 9 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor any of the Registered Stockholders have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor any of the Registered Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Registered Stockholders are offering to sell, and seeking offers to buy, shares of their common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor any of the Registered Stockholders have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by the Registered Stock

View Full Filing

View this S-1/A filing on SEC EDGAR